Capsid-Modified rAAV Vectors for Higher Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing recombinant adeno-associated virus (rAAV) vectors exhibit variable transduction efficiency across different cells and tissues, limiting their effectiveness in gene therapy applications, particularly due to factors like EGFR-PTK signaling and ubiquitination of AAV capsid proteins, which hinder nuclear transport and transgene expression.
Innovation Solution
Development of modified rAAV vectors with amino acid substitutions, specifically in surface-exposed residues such as lysine, serine, and threonine, to enhance transduction efficiency and stability, reducing ubiquitination and immunogenicity, and improving viral infectivity for targeted mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If wild-type rAAV vectors are used, then the vectors can infect a variety of cell and tissue types, but the transduction efficiency varies greatly and is limited in many applications
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at particular positions (e.g., K497R, K500R, K502R, K505R, K508R, K511R, K514R, K517R, K520R, K523R, K526R, K529R, K532R, K535R, K538R, K541R, K544R, K547R, K550R, K553R, K556R, K559R, K562R, K565R, K568R, K571R, K574R, K577R, K580R, K583R, K586R, K589R, K592R, K595R, K598R, K601R, K604R, K607R, K610R, K613R, K616R, K619R, K622R, K625R, K628R, K631R, K634R, K637R, K640R, K643R, K646R, K649R, K652R, K655R, K658R, K661R, K664R, K667R, K670R, K673R, K676R, K679R, K682R, K685R, K688R, K691R, K694R, K697R, K700R, K703R, K706R, K709R, K712R, K715R, K718R, K721R, K724R, K727R, K730R, K733R, K736R, K739R, K742R, K745R, K748R, K751R, K754R, K757R, K760R, K763R, K766R, K769R, K772R, K775R, K778R, K781R, K784R, K787R, K790R, K793R, K796R, K799R, K802R, K805R, K808R, K811R, K814R, K817R, K820R, K823R, K826R, K829R, K832R, K835R, K838R, K841R, K844R, K847R, K850R, K853R, K856R, K859R, K862R, K865R, K868R, K871R, K874R, K877R, K880R, K883R, K886R, K889R, K892R, K895R, K898R, K901R, K904R, K907R, K910R, K913R, K916R, K919R, K922R, K925R, K928R, K931R, K934R, K937R, K940R, K943R, K946R, K949R, K952R, K955R, K958R, K961R, K964R, K967R, K970R, K973R, K976R, K979R, K982R, K985R, K988R, K991R, K994R, K997R, K1000R) on the capsid protein surface to enhance transduction efficiency while preserving the ability to infect various cell types
Solution Approach 2:
The patent applies parameter changes by systematically substituting lysine residues with arginine residues at multiple positions on the capsid protein, thereby changing the chemical properties (charge, polarity) of the capsid surface to improve transduction efficiency and reduce ubiquitination while maintaining broad cell type infectivity
2Ease of manufacture
If unmodified rAAV vectors are used, then the production process is simpler, but the transduction efficiency is lower and particle requirements are higher
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions (lysine to arginine) in the capsid protein sequence to enhance transduction efficiency, while the production process remains fundamentally the same as wild-type rAAV production, thus maintaining ease of manufacture while improving productivity
3Stability of the object's composition
If wild-type AAV capsid proteins are used, then the vectors are more stable in production, but they are more immunogenic and undergo ubiquitination that hinders nuclear transport
Solution Approach 1:
The patent applies local quality by specifically targeting surface-exposed lysine residues on the capsid protein for substitution with arginine residues. This localized modification reduces immunogenicity and ubiquitination at the protein surface while preserving the overall structural stability and production characteristics of the wild-type capsid
Solution Approach 2:
The patent applies parameter changes by substituting lysine residues (positively charged, prone to ubiquitination) with arginine residues (positively charged, more stable) at multiple positions on the capsid surface, thereby changing the chemical stability and immunogenicity parameters while maintaining production stability
Data Source
AI summary
Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.